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Objectives We sought to evaluate the characteristics, treatments, and outcomes of patients with preserved and reduced
systolic function heart failure (HF).
Background Heart failure with preserved systolic function (PSF) is common but not well understood.
Methods This analysis of the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With
Heart Failure) registry compared 20,118 patients with left ventricular systolic dysfunction (LVSD) and 21,149 patients
with PSF (left ventricular ejection fraction [EF]40%). Sixty- to 90-day follow-up was obtained in a pre-specified 10%
sample of patients. Analyses of patients with PSF defined as EF50% were also performed for comparison.
Results Patients with PSF (EF 40%) were more likely to be older, female, and Caucasian and to have a nonischemic
etiology. Although length of hospital stay was the same in both groups, risk of in-hospital mortality was lower in
patients with PSF (EF 40%) (2.9% vs. 3.9%; p  0.0001). During 60- to 90-day post-discharge follow-up, pa-
tients with PSF (EF 40%) had a similar mortality risk (9.5% vs. 9.8%; p  0.459) and rehospitalization rates
(29.2% vs. 29.9%; p  0.591) compared with patients with LVSD. Findings were comparable with those with
PSF defined as EF 50%. In a risk- and propensity-adjusted model, there were no significant relationships be-
tween discharge use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker or beta-blocker
and 60- to 90-day mortality and rehospitalization rates in patients with PSF.
Conclusions Data from the OPTIMIZE-HF registry reveal a high prevalence of HF with PSF, and these patients have a similar
post-discharge mortality risk and equally high rates of rehospitalization as patients with HF and LVSD. Despite
the burden to patients and health care systems, data are lacking on effective management strategies for pa-
tients with HF and PSF. (Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart
Failure [OPTIMIZE-HF]); http://www.clinicaltrials.gov/ct/show/NCT00344513?order1; NCT00344513) (J Am
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August 21, 2007:768–77 Heart Failure Outcomes and Systolic Functionsubstantial portion of patients with heart failure (HF)
ave relatively normal or preserved systolic function (PSF).
eart failure with PSF has been defined as the presence of
F symptoms in patients with a documented left ventric-
lar ejection fraction (EF) of 40% or 50%, depending
n the study (1,2). Clinical trials of HF therapies have
ypically required patients to have left ventricular systolic
ysfunction (LVSD) with reduced EF (3–7). Consequently,
ew data are available in patients with HF and PSF that
escribe outcomes or guide management strategies; this lack
f evidence is problematic, because these patients are fre-
uently hospitalized for HF (2,3,5). Earlier studies suggest
hat patients with HF and PSF differ from those with HF
nd LVSD in both their characteristics and clinical out-
omes, but these studies are limited by small and/or selective
opulations (8–10).
The OPTIMIZE-HF (Organized Program to Initiate
ifesaving Treatment in Hospitalized Patients With Heart
ailure) is a large national registry and performance-
mprovement program for patients hospitalized for HF (11).
he OPTIMIZE-HF registry included patients with and
ithout reduced EF; thus, it presents an opportunity to
valuate the characteristics, treatments, and outcomes of a
arge unselected population of patients with PSF who
equire hospitalization to manage their HF. The present
eport describes the characteristics, hospital course, and
ost-discharge outcomes of patients with LVSD and pa-
ients with PSF at the time of hospitalization for HF.
ethods
he OPTIMIZE-HF design and methods have been pub-
ished previously (11,12). Briefly, eligible patients were
hose hospitalized with new-onset or worsening pre-
xisting HF as the primary cause of admission or those with
ignificant HF symptoms that developed during the hospi-
alization where HF was the primary discharge diagnosis.
atients were considered to have PSF if EF was docu-
ented as 40% or, if not quantified, qualitatively normal
r mildly impaired. Because variable definitions of PSF have
een used in earlier studies, additional analyses for patients
ith PSF and a documented EF between 40% and 50% as
ell as patients with a documented EF 50% were also
onsidered for comparison. Patients considered to have
VSD were those with EF 40% or moderate/severe left
entricular dysfunction by qualitative assessment.
Study components included a web-based registry, which
ollected detailed patient data including demographics,
edical history, signs and symptoms, medications, labora-
ories, diagnostic testing, procedures, discharge status, and
dherence to performance indicators. Sites could view and
nalyze their adherence to benchmarked performance mea-
ures in real time. The registry coordinating center was
utcome Sciences (Cambridge, Massachusetts). The
rocess-of-care improvement program provided participat-
ng hospitals with a comprehensive tool kit including tvidence-based best-practice al-
orithms, standing orders, and
ischarge checklists. These tools
ere based on published HF
uidelines from the American
eart Association (AHA) and
merican College of Cardiology
ACC) and the Heart Failure
ociety of America (HFSA)
13,14). Algorithms focused on
atients with LVSD, because no
vidence-based therapies were
vailable for PSF. Recommenda-
ions for PSF included complete
ischarge instructions, smoking-cessation counseling, anti-
oagulation and ventricular rate control for atrial fibrillation,
ypertension control, and diuretics for volume control.
The incidence of death or rehospitalization within 60 to
0 days was prospectively collected on a pre-specified 10%
ubset of the total OPTIMIZE-HF population (11,12).
he protocol was approved by each participating center’s
nstitutional review board or by a central institutional review
oard. Written informed consent was obtained from pa-
ients who participated in the follow-up data collection
efore enrollment.
All statistical analyses were conducted independently by
he Duke Clinical Research Institute, Durham, North
arolina. Data are reported as mean and standard deviation
or continuous variables or percentages of nonmissing values
or categoric variables. Patient characteristics and treat-
ents were compared using the Pearson chi-square test for
ategoric variables and the Wilcoxon test for continuous
ariables. Performance measures were constructed among
ligible patients without specific contraindications, intoler-
nce, or other physician-documented reasons, as previously
escribed (15). The unadjusted relationships between pres-
nce of PSF and outcomes were tested using Pearson
hi-square test for categoric variables and the Wilcoxon test
or continuous variables. Previously developed models of
n-hospital mortality, mortality from hospital discharge to
0 days, and post-discharge mortality or rehospitalization
ere used to adjust for significant covariates (12). Logistic
egression modeling was used for in-hospital mortality. Cox
roportional hazard modeling was applied to all-cause
ortality in the follow-up period, and logistic regression
odeling was used for the composite end point. The
ssumption of linearity was evaluated for the continuous
easures using restricted cubic splines, and, when violated
ppropriate linear spline transformations were applied (Ap-
endix). For the Cox model, the proportional hazard
ssumption was assessed. Variable selection techniques in-
luded backward, forward-stepwise, and bootstrapping the
ackward selection process of 100 replicated samples to
btain the percentage of time each variable was retained in
he model and the variation in parameter estimates across
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ARB  angiotensin
receptor blocker
EF  ejection fraction
HF  heart failure
LVSD  left ventricular
systolic dysfunction
PSF  preserved systolic
functionhe bootstrapped samples. A p value of 0.05 was used for
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Heart Failure Outcomes and Systolic Function August 21, 2007:768–77oth entry and retention in the model during the selection
rocess. The variables that were common in each and
hosen in at least 75% of the replicated samples were
etained. The final model for each end point was also
ootstrapped to obtain an estimate of the C-statistic after
ccounting for the overfitting of testing and creating the
odel on the same population. All the variables retained in
he final models are used as adjusted variables (Appendix).
ropensity score analysis was used to account for medication
election bias when looking at the association between the
edication and outcome. The variables selected for the
core were applied to a logistic regression model with the
robability of receiving the medication generated as the
core. Generalized estimating equations were used to ac-
ount for the correlation of the data within the same
ospital in the adjusted models. For all statistical analyses,
AS version 8.2 (SAS Institute, Cary, North Carolina) was
sed.
esults
aseline characteristics. Of the 48,612 patients hospital-
zed for HF at 259 hospitals, 41,267 (84.9%) had data for
F or a qualitative assessment of left ventricular function
nd were included in this analysis. Overall, patients enrolled
n the OPTIMIZE-HF registry displayed a wide distribu-
ion of EF values (Fig. 1). Of the patients with left
entricular function assessed, 21,149 (51.2%) had EF40%
r a qualitatively normal/mildly impaired EF and were
lassified as having HF with PSF. Among those patients
ith PSF and a quantitative EF of 40%, 7,321 patients
ad a documented EF 40% and 50% and 10,072
atients had a documented EF 50%. The baseline char-
cteristics, history, and HF characteristics on admission for
ll patients included in this analysis are summarized in
Figure 1 Distribution of Patients’ LVEFs
Histogram of left ventricular ejection fraction (LVEF) in patients hospitalized with aable 1. Compared with LVSD patients, those with PSF
ere significantly older and were more often women; this
roup also included significantly fewer African Americans.
atients with PSF were also more likely to have a history of
ypertension and a higher systolic blood pressure on admis-
ion. As expected, the mean EF was in the normal range for
atients with PSF, but it was 24.3  7.7 in those with
VSD, a lower value than that typically observed in HF
linical trials (3). The etiology of HF was ischemic in a
igher percentage of patients with LVSD, whereas a hyper-
ensive etiology was more common in those with PSF. The
F symptoms and routine laboratory measurements were
imilar in both groups on admission. B-type natriuretic
eptide levels, though significantly lower in patients with
SF, were markedly elevated in both groups, consistent
ith acutely decompensated HF. On admission, a smaller
ercentage of patients with PSF were receiving angiotensin-
onverting enzyme (ACE) inhibitors, beta-blockers, aldo-
terone antagonists, digoxin, and loop diuretics, but more
SF patients were receiving amlodipine and angiotensin
eceptor blockers (ARB). There were significant differences
n characteristics seen within the PSF group in patients with
F between 40% and 50% and those with EF50% (Table
). The magnitude of these differences was generally smaller
han those observed between patients with PSF and LVSD.
ospital course and management. Intravenous vasodila-
ors were used in 17% of LVSD patients and 12% of PSF
atients (p  0.0001). Inotropes were used infrequently,
ith 12% and 4% of LVSD and PSF patients, respectively,
eceiving therapy (p  0.0001). The overall use of in-
ospital procedures (coronary angiography, cardioversion,
echanical ventilatory or circulatory support, and so forth)
as low, although a higher proportion of LVSD patients
eceived a procedure compared with PSF patients (29% vs.
ry discharge diagnosis of heart failure.prima
B*
d
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Table 1 Baseline Patient Characteristics, Heart Failure History, and Findings on Admission by Ventricular Function
Characteristics at Admission
Patients With LVSD
(n  20,118)
Patients With PSF
(n  21,149)
p Value
(LVSD vs.
PSF)
Patients With
40% < EF < 50%
(n  7,321)
Patients With
EF >50%
(n  10,072)
p Value
(40% < EF < 50%
vs. EF >50%)
Demographics
Mean age (yrs) 70.4 14.3 75.1 13.1 0.0001 74.3 13.0 75.6 13.1 0.0001
Male (%) 62 38 0.0001 48 32 0.0001
Caucasian (%) 71 77 0.0001 78 77 0.086
African American (%) 21 15 0.0001 15 15 0.880
Medical history (%)
Diabetes, insulin-treated 15 17 0.0001 18 16 0.013
Diabetes, noninsulin-treated 24 26 0.009 26 25 0.418
Hypertension 66 76 0.0001 74 77 0.0001
Hyperlipidemia 34 32 0.0001 35 31 0.0001
Atrial arrhythmia 28 33 0.0001 33 32 0.179
Vital signs on admission
Median body weight (kg
[25th, 75th percentile])
78.5 [65.8, 94.0] 78.9 [64.0, 97.5] 0.019 79.4 [65.0, 97.5] 78.0 [63.5, 97.1] 0.002
Mean heart rate (beats/min) 89 22 85 21 0.0001 86 21 84 21 0.0001
Mean SBP (mm Hg) 135 31 149 33 0.0001 147 33 150 33 0.0001
Mean DBP (mm Hg) 77 19 76 19 0.0001 77 19 75 19 0.0001
Etiology (%)
Ischemic 54 38 0.0001 49 32 0.0001
Hypertensive 17 28 0.0001 22 31 0.0001
Idiopathic 18 21 0.0001 18 23 0.0001
Findings on admission (%)
Acute pulmonary edema 3 2 0.270 2 3 0.362
Chest pain 23 24 0.512 24 24 0.618
Uncontrolled hypertension 9 12 0.0001 11 12 0.075
Dyspnea at rest 44 44 0.194 46 44 0.022
Dyspnea on exertion 63 62 0.206 62 62 0.719
Rales 63 65 0.001 67 63 0.0001
Lower extremity edema 62 68 0.0001 68 68 0.211
Jugular venous pulsation 33 26 0.0001 32 29 0.0005
Left ventricular EF (mean %) 24.3 7.7 54.7 10.2 0.0001 45.0 4.0 61.8 7.0 0.0001
Laboratory values
Mean serum sodium (mEq/l) 137.7 4.6 137.9 4.8 0.0001 137.9 4.7 137.8 4.8 0.090
Median serum creatinine (mg/dl
[25th, 75th percentile])
1.4 [1.1, 1.9] 1.3 [1.0, 1.8] 0.0001 1.3 [1.0, 1.9] 1.2 [1.0, 1.8] 0.0001
Mean serum hemoglobin (g/dl) 12.5 2.0 11.9 2.0 0.0001 11.9 2.0 11.8 2.0 0.0001
Median BNP (pg/ml
[25th, 75th percentile])
1,170.0 [603.0, 2,280.0] 601.5 [320.0, 1,190.0] 0.0001 757.0 [400.0, 1,460.0] 537.0 [287.0, 996.5] 0.0001
Median troponin I (ng/ml
[25th, 75th percentile])
0.1 [0.1, 0.3] 0.1 [0.0, 0.3] 0.0001 0.1 [0.1, 0.3] 0.1 [0.0, 0.3] 0.0001
Medications on admission (%)
ACE inhibitor 45 36 0.0001 38 34 0.0001
ARB 11 13 0.0001 12 14 0.0001
Amlodipine 5 10 0.0001 9 11 0.0001
Aldosterone antagonist 10 5 0.0001 6 4 0.0001
Beta-blocker 56 52 0.0001 54 50 0.0001
Loop diuretic 63 58 0.0001 59 57 0.039
Digoxin 30 17 0.0001 19 15 0.0001
Aspirin 42 38 0.0001 41 36 0.0001
Antiarrhythmic 13 8 0.0001 10 8 0.0001
Hydralazine 3 3 0.021 3 3 0.346
Nitrate 22 21 0.013 23 20 0.0001
Statin* 40 39 0.021 41 37 0.0001
Statin use among patients with coronary artery disease, cerebrovascular disease/transient ischemic attack, diabetes, hyperlipidemia, or peripheral vascular disease.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; BNP  B-type natriuretic peptide; DBP  diastolic blood pressure; EF  ejection fraction; LVSD  left ventricular systolic
ysfunction; PSF  preserved systolic function; SBP  systolic blood pressure; SD  standard deviation.
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Heart Failure Outcomes and Systolic Function August 21, 2007:768–778%; p  0.0001). At the time of discharge, statistically
ignificant differences in weight loss, HF symptoms, and
ertain other clinical variables were observed between pa-
ients with LVSD and PSF (Table 2). These statistical
ifferences were likely detected owing to the large popula-
ion size, but the values for these variables were clinically
imilar. Overall, patients with LVSD and PSF were equally
ikely to be discharged with symptoms of congestion.
atterns of medication use at hospital discharge were
omewhat similar to those at admission, with a lower
ercentage of patients with PSF than with LVSD receiving
CE inhibitors and beta-blockers (Table 2). Whereas the
ercentage of patients with LVSD taking an ACE inhibitor
ncreased from 45% on admission to 62% at hospital
ischarge (p 0.0001), the increase in ACE inhibitor usage
n the PSF group was smaller, rising from 36% to 48% (p 
.0001). Similarly, beta-blocker usage increased from 56%
o 73% in patients with LVSD (p  0.0001) but increased
rom 52% to 60% in those with PSF (p  0.0001). There
atient Examination Findings and Clinical Status at Hospital Disch
Table 2 Patient Examination Findings and Clinical Status at Ho
Characteristics at Discharge
Patients With LVSD
(n  20,118)
Patients With PSF
(n  21,149)
Median weight change
from admission (kg
[25th, 75th percentile])
2.0 [5.0, 0.0] 2.0 [4.5, 0.0]
Median BNP (pg/ml
[25th, 75th percentile])
782.0 [408.0, 1,650.0] 432.0 [223.0, 820.5
Median serum creatinine (mg/dl
[25th, 75th percentile])
1.4 [1.1, 1.9] 1.3 [1.0, 1.9]
Mean heart rate (beats/min) 77.0 14.1 74.9 14.0
Mean SBP (mm Hg) 119.0 21.0 129.4 22.3
Jugular venous pulsation (%) 4 2
Rales (%) 15 15
Lower extremity edema (%) 25 28
HF symptoms at discharge (%)
Worse 2.4 1.8
Unchanged 1.8 1.1
Better, symptomatic 41.0 41.5
Better, asymptomatic 50.0 51.1
Unable to determine 4.9 4.5
Medications at discharge (%)
ACE inhibitor 62 48
ARB 11 13
Amlodipine 5 10
Aldosterone antagonist 18 8
Beta-blocker 73 60
Loop diuretic 77 73
Digoxin 38 19
Aspirin 51 45
Antiarrhythmic 15 9
Hydralazine 5 4
Nitrate 24 25
Statin* 42 39
Statin use among patients with coronary artery disease, cerebrovascular disease/transient ische
Abbreviations as in Table 1.ere some modest differences in treatment patterns within ghe PSF group in patients with EF between 40% and 50%
nd those with EF 50% (Table 2).
Length of hospital stay was similar in both groups,
veraging 6.0 6.4 days (median 4 [interquartile range 3 to
] days) in patients with LVSD and 5.7 5.5 days (median
[3 to 7] days) in those with PSF. Unadjusted in-hospital
ortality rates were significantly higher in patients with
VSD: 3.9% versus 2.9% for those with PSF (unadjusted
dds ratio [OR] 1.34; 95% confidence interval [CI] 1.19 to
.50; p  0.0001). There were no differences in in-hospital
utcomes seen within the PSF group in patients with EF
etween 40% and 50% and those with EF 50% (3.0% vs.
.9%, respectively; p  0.65) (Table 3).
utcomes after hospital discharge. There was no signif-
cant difference in unadjusted all-cause mortality during 60-
o 90-day post-discharge follow-up (Table 3, Fig. 2). Both
roups experienced similarly high event rates: 9.8% in
atients with LVSD and 9.5% in those with PSF (p 
.459). There were no significant differences between
by Ventricular Function
l Discharge by Ventricular Function
Value
VSD vs.
PSF)
Patients With
40% < EF < 50%
(n  7,321)
Patients With
EF >50%
(n  10,072)
p Value
(40% < EF < 50%
vs. EF >50%)
0.0001 2.0 [4.5, 0.0] 1.9 [4.1, 0.0] 0.006
0.0001 527.5 [282.0, 1,027.0] 390.0 [206.0, 736.0] 0.0001
0.0001 1.4 [1.0, 1.9] 1.3 [1.0, 1.8] 0.0001
0.0001 74.9 13.8 74.5 13.9 0.103
0.0001 128.3 22.0 130.3 22.5 0.0001
0.0001 2 2 0.004
0.866 15 15 0.958
0.0001 28 28 0.692
0.0001 0.993
1.8 1.7
1.2 1.2
42.2 42.3
50.1 50.2
4.7 4.6
0.0001 52 44 0.0001
0.0001 12 14 0.0007
0.0001 10 11 0.002
0.0001 10 7 0.0001
0.0001 66 57 0.0001
0.0001 74 72 0.001
0.0001 22 17 0.0001
0.0001 48 43 0.0001
0.0001 11 9 0.0001
0.006 5 4 0.0158
0.256 28 23 0.0001
0.0001 42 37 0.0001
ack, diabetes, hyperlipidemia, or peripheral vascular disease.arge
spita
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August 21, 2007:768–77 Heart Failure Outcomes and Systolic Functionion (12% in both groups) or in rehospitalizations (29.9% in
hose with LVSD vs. 29.2% in those with PSF; p  0.591)
n the early follow-up period. The occurrence of death from
ny cause and/or rehospitalization was similarly high in both
roups: 36.1% in those with LVSD and 35.3% in those with
SF (p  0.577). Importantly, within the PSF group, there
as no difference in post-discharge outcomes in patients
ith EF between 40% and 50% compared with those with
F 50% (Table 3).
pplication of performance measures. The ACC and
HA have defined 5 performance measures for inpatients
ospitalized with HF (16), 3 of which are irrespective of
F: receipt of complete discharge instructions, smoking-
essation counseling, and warfarin for atrial fibrillation. In
he OPTIMIZE-HF registry, adherence to these measures
as more frequent in patients with LVSD than in those
ith PSF (Fig. 3).
ultivariable analyses. After multivariable adjustment,
he OR for in-hospital mortality for LVSD versus PSF was
.28 (95% CI 1.13 to 1.46; p  0.0002). The adjusted
n-hospital mortality risk for patients with EF between 40%
nd 50% compared with those with EF 50% was similar:
R 1.02 (95% CI 0.86 to 1.20; p 0.831). As a continuous
ariable, EF was an independent predictor of in-hospital
ortality on multivariable analysis. In-hospital mortality
ecreased 17% for every 10% increase in EF up to 38% (OR
.83, 95% CI 0.76 to 0.91; p  0.0001). Left ventricular
unction was not further predictive of in-hospital mortality
or EF values above 38%. The EF did not predict follow-up
ll-cause mortality or the combination of all-cause mortality
nd rehospitalization in the multivariable model.
nfluence of pharmacologic therapy. In a risk- and
ropensity-adjusted model, there were no significant rela-
ionships between discharge use of a beta-blocker or an
CE inhibitor/ARB and 60- to 90-day mortality and
ehospitalization rates in patients with PSF (Table 4). In
ontrast, patients with LVSD taking a beta-blocker at
ischarge experienced significantly lower risk- and
ropensity-adjusted all-cause mortality during 60 to 90 days
f follow-up than those not taking a beta-blocker. In
ost-Discharge 60- to 90-Day Clinical Outcomes by Ventricular Fun
Table 3 Post-Discharge 60- to 90-Day Clinical Outcomes by Ve
Outcomes
Patients With LVSD
(n  20,118)
Patients With PSF
(EF >40%)
(n  21,149)
In-hospital mortality: all patients
(% [95% CI])
3.9 [3.6–4.2] 2.9 [2.7–3.1]
Follow-up cohort (n 2,604] (n 2,294]
Post-discharge mortality at
60–90 days (% [95% CI])
9.8 [8.2–11.4] 9.5 [7.9–11.0]
Rehospitalization at 60–90 days
(% [95% CI])
29.9 [28.1–31.6] 29.2 [28.1–31.6]
Post-discharge
mortality/rehospitalization at
60–90 days (% [95% CI])
36.1 [34.3–37.9] 35.3 [33.4–37.3]
I  confidence interval; other abbreviations as in Table 1.atients with LVSD, there was also lower risk- andropensity-adjusted mortality or rehospitalization rates as-
ociated with beta-blocker use, as well as a significant
elationship between discharge use of ACE inhibitor/ARB
nd 60- to 90-day mortality or rehospitalization.
iscussion
eart failure with PSF. The OPTIMIZE-HF registry
rovides a large dataset from which the characteristics,
reatments, quality of care, and early outcomes for patients
ith HF and PSF can be evaluated. These results confirm
revious observations that PSF is very common and ac-
ounts for a large proportion of patients hospitalized with
F outside the clinical trial setting (2–7). The ADHERE
Acute Decompensated Heart Failure National Registry)
tudy included observations from more than 26,000 patients
ospitalized with HF and PSF, and the ADHERE findings
ere remarkably similar to those of the OPTIMIZE-HF
egistry (2). Both datasets confirm that, demographically,
Figure 2 Survival After Hospital Discharge
in Patients With LVSD Compared With PSF
Kaplan-Meier survival curves after hospital discharge in patients with left ven-
tricular systolic dysfunction (LVSD) compared with patients with preserved sys-
tolic function (PSF) in the follow-up cohort.
lar Function
p Value
SD vs. PSF)
Patients With
40% < EF < 50%
(n  7,321)
Patients With
EF >50%
(n  10,072)
p Value
(40% < EF < 50%
vs. EF >50%)
0.0001 3.0 [2.6–3.4] 2.9 [2.5–3.2] 0.647
(n 962] (n 1,014]
0.459 9.2 [6.8–11.6] 9.3 [7.0–11.5] 0.887
0.591 29.0 [26.1–31.9] 30.9 [28.0–33.7] 0.366
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e women, less likely to be African American, and more
ikely to have hypertension. Heart failure with PSF is also
ore likely to have a hypertensive rather than ischemic
tiology (2,17). Despite more frequent hypertension and
iabetes, African-American HF patients were more likely to
ave LVSD, which may reflect a substantially younger age
t presentation. Data from both studies show that patients
ith PSF were not clinically distinguishable from those with
VSD in terms of HF symptoms or physical examination
ndings at admission, despite the differences in underlying
atient characteristics and etiology. This clinical similarity
Figure 3 Discharge Medications and Application of Performanc
Note that only discharge instructions, smoking cessation counseling, and anticoag
performance measures for which heart failure patients with PSF are included. ACE
rone antagonist; ARB  angiotensin receptor blocker; other abbreviations as in Fig
Discharge Medications and Risk- and PropensityHospital Discharge in P tients With Reduc d an
Table 4 Discharge Medications and Risk- anHospital Discharge in Patients With
Outcome Ha
LVSD
Mortality at 60–90 days
ACE inhibitor/ARB vs. no ACE inhibitor/ARB
Beta-blocker vs. no beta-blocker
Mortality and/or rehospitalization at 60–90 days
ACE inhibitor/ARB vs. no ACE inhibitor/ARB
Beta-blocker vs. no beta-blocker
PSF
Mortality at 60–90 days
ACE inhibitor/ARB vs. no ACE inhibitor/ARB
Beta-blocker vs. no beta-blocker
Mortality and/or rehospitalization at 60–90 days
ACE inhibitor/ARB vs. no ACE inhibitor/ARB
Beta-blocker vs. no beta-blockerAbbreviations as in Table 1.etween acutely decompensated HF patients with and
ithout PSF has been noted previously (2,18). However,
efinitions for PSF have varied, and the choice of an
ppropriate EF cutoff has been subjected to debate. In the
resent analysis, findings were mostly similar whether PSF
as defined as EF 40% or EF 50%, although patients
ith EF 50% were even more likely to be female and less
ikely to have an ischemic etiology.
Although both groups lost a similar amount of weight
uring the hospitalization, only one-half of the patients in
ach group had complete resolution of symptoms, and both
roups were equally likely to be discharged with persistent
asures in Patients With LVSD Compared With PSF
for AF are current American College of Cardiology/American Heart Association
iotensin-converting enzyme inhibitor; AF  atrial fibrillation; Ald Ant  aldoste-
sted Outcomes Aftererved Systolic Function
opensity-Adjusted Outcomes After
uced and Preserved Systolic Function
atio
95% Confidence
Limits Chi-Square p Value
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August 21, 2007:768–77 Heart Failure Outcomes and Systolic Functionigns of congestion. There was no significant difference in
ospital length of stay for the 2 groups, and both groups
xhibited similar change in HF symptom status. As in the
DHERE study (2), in-hospital mortality rates in patients
ith PSF were slightly lower than in patients with LVSD.
otably, at the time of hospital discharge, patients with
SF were less likely to receive ACE inhibitors, beta-
lockers, or aldosterone antagonists, a result which mirrors
he ADHERE report (2). In the OPTIMIZE-HF registry,
t was further noted that patients with PSF were also less
ikely to receive aspirin and statins.
The use of a prespecified follow-up cohort in the
PTIMIZE-HF registry contributes new observations and
nsights into the early post-discharge period. The data show
hat although patients with PSF are more likely to survive
n HF hospitalization than patients with LVSD, they
emain at equally high risk for mortality and for mortality or
ehospitalization in the first 60 to 90 days after index
ospitalization. A study among patients hospitalized with
ew-onset HF also showed that the post-discharge survival
f patients with HF with preserved EF was similar to that
f patients with reduced EF (19). The 90-day post-
ischarge mortality rates for patients with reduced and
reserved EF HF in that study were similar to those
bserved in the OPTIMIZE-HF registry. However, that
tudy was limited in that only 42% of potentially eligible
atients had a documented assessment of left ventricular
unction and it drew from only a single province in
anada (19). An analysis of 4,596 patients from a single
ommunity showed that, over a 15-year period, the
revalence of HF with preserved EF increased but the
ate of death did not change (20).
Despite this alarming risk, clinical trial data to support
reatment approaches are sparse for patients with HF and
SF. Current HF guideline recommendations for patients
ith PSF include control of systolic and diastolic hyperten-
ion, ventricular rate control in patients with atrial fibrilla-
ion, and use of diuretics to control pulmonary congestion
nd peripheral edema (17). The OPTIMIZE-HF registry
eveals new insights into the quality of care provided to
atients with PSF. Patients with PSF were admitted to the
ospital with markedly elevated systolic blood pressure.
atients with PSF were slightly less likely than patients with
VSD to be treated with diuretics, at both admission and
ischarge, despite similar signs and symptoms of conges-
ion. This group was less likely than patients with LVSD to
eceive anticoagulation therapy for atrial fibrillation,
moking-cessation counseling, or complete discharge in-
tructions, quality measures that should be applied to all
atients with HF regardless of EF. Despite the large
umber of patients that are affected, overall quality of HF
are for patients with PSF lags behind that provided to
atients with HF with reduced EF. Although specific data
re lacking on effective therapeutic strategies in this popu-
ation, the OPTIMIZE-HF registry demonstrates an op-
ortunity to improve the care of these patients. eThe CHARM (Candesartan in Heart Failure: Assess-
ent of Reduction in Mortality and Morbidity)-Preserved
tudy observed a reduction in HF hospitalizations for
utpatients with HF and PSF who were treated with the
RB candesartan in addition to standard background ther-
py (21). In the OPTIMIZE-HF registry, patients with
SF were more likely to be treated with an ARB than were
atients with LVSD. An ACE inhibitor or ARB and
eta-blockers may be potentially beneficial in patients with
F and PSF who also have other indications for these
gents, such as coronary artery disease, diabetes, or hyper-
ension. However, no association was observed between the
se of ACE inhibitor/ARB or beta-blockers at the time of
ospital discharge and clinical outcomes in the first 60 to 90
ays of follow-up in patients admitted with HF and PSF.
he benefits observed in the CHARM-Preserved study
ccurred over a median follow-up of 36.6 months, and the
aplan-Meier curves did not visually appear to separate
ntil approximately 6 months (21). Thus, a relationship may
ave been observed in OPTIMIZE-HF if follow-up had
een longer. No other medications have proven to be
ffective in patients with HF and PSF. In the Digitalis
nvestigation Group ancillary trial, digoxin had no effect on
atural history end points such as mortality and all-cause or
ardiovascular hospitalizations in ambulatory patients with
hronic mild-to-moderate diastolic HF and normal sinus
hythm (22). It must also be emphasized that the
PTIMIZE-HF registry was not a randomized trial, and it
as not prospectively designed to test the efficacy of
harmacologic therapy in the PSF population. Given the
igh post-discharge clinical event rate and the lack of
roven effective therapies for this condition, there is a clear
eed to test treatment strategies for patients with HF and
SF in randomized clinical trials.
Although these OPTIMIZE-HF data are consistent
ith earlier observations in patients with PSF, it should be
oted that the OPTIMIZE-HF registry involved a much
arger and more diverse group of patients than the majority
f earlier reports (3–6,19,20,23,24). With the added con-
ribution of early post-discharge outcomes, these data may
e valuable in designing the prospective randomized trials
hat are much needed to identify agents to reduce risk and
mprove outcomes in patients with HF and PSF.
tudy limitations. The results of the present study should
e interpreted in the context of several limitations. The
resent observations include only hospitalized patients with
F, a population known to be at increased risk of adverse
utcomes, including readmission for HF and mortality after
ospital discharge (25,26). In addition, left ventricular
unction was not assessed in 7,345 patients (15%), and these
atients were excluded from the analysis. Some of the
bserved differences may not be clinically relevant, although
hey were statistically significant because of the large
umber of patients studied overall. Follow-up data were
ollected only from a pre-specified subset of patients and
xtended only 60 to 90 days after hospital discharge. The
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Heart Failure Outcomes and Systolic Function August 21, 2007:768–77ollow-up period may have been too short to observe
otential efficacy of pharmacologic interventions. Out-
omes may have been different over longer follow-up.
edication contraindications and intolerance were as
ocumented in the medical record. Some patients may
ave had contraindications or intolerance that were
resent but not documented. This study was not a
rospective randomized clinical trial, and residual mea-
ured and unmeasured confounders may have influenced
linical outcome.
onclusions
reserved systolic function was present in a large propor-
ion of patients enrolled in this large unselected repre-
entative registry of patients hospitalized with HF. Al-
hough patients with HF and PSF differ significantly
rom those with HF and LVSD, both groups experience
imilarly high rates of mortality and morbidity. Further-
ore, no differences in clinical outcomes were seen with
ifferent definitions for PSF. Specific therapeutic strate-
ies are lacking for patients with HF and PSF. Given the
ubstantial risk of adverse clinical events and the lack of
n appropriate body of evidence to guide management in
atients with HF and PSF, large well designed clinical
rials are critically needed to identify effective manage-
ent strategies for this population.
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APPENDIX
or variables used in the models and linear spline transformations for
ontinuous variables, please see the online version of this article.
